Building A Quality & Safety Infrastructure: The Harris Center Case Study is starting in

Clozapine Use Still Limited

OPEN MINDS The Behavioral Health & Social Service Industry Analyst Industry News Although it has been on the market since February 1990, only about 13% of the candidates for this new anti-schizophrenic drug are getting it according to Sandoz Pharmaceuticals Corporation the developer of the medication. Courts have ruled that Medicaid should pay for the drug, but evidently budget considerations and administrative roadblocks have hampered implementation of the court orders. The National Association of Mental Health Program Directors believes that all states will eventually pay for the drug . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.